Hvsen Biotechnology Co. Ltd. Class A

Hvsen Biotechnology Co. Ltd. Class A

SSZSE:300871
18.93
CNY
+0.56
(+3.05%)
1.55EPS
13.11P/E
4.26BMarket Cap
Apr 29Next Earn
Hvsen Biotechnology Co. Ltd. Class A
SZSE:300871
(Shenzhen Stock Exchange)

Recent

price

18.93

P/E

ratio

13.11

div

yld

2.80%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.56
3.35
3.51
3.44
5.28
6.01
6.18
6.14
7.24
8.87
8.48
Revenue per Share
0.3
0.74
0.59
0.55
1.02
0.8
0.32
0.1
-0.12
1.33
1.61
Basic EPS, GAAP
0.19
0.2
-0.11
-0.14
-1.24
-2.68
-2.01
-0.55
-0.91
0.75
- -
Free Cash Flow per Basic Share
0.12
0.2
0.18
0.13
0.04
0.29
0.38
0.35
0.36
0.26
0.53
Dividend per Share
1.29
1.86
2.61
3.05
8.32
9.74
9.28
9.1
8.79
10.74
11.43
Book Value per Share
1.05
1.32
2.1
2.25
7.74
9.08
8.64
8.47
8.1
10.19
10.86
Tangible Book Value per Share
166
119
120
124
147
166
165
166
166
190
201
Basic Weighted Avg Shares
258
400
422
427
777
996
1,023
1,020
1,200
1,681
1,706
Sales/Revenue/Turnover
21.62
26.39
22.63
19.5
22.9
13.67
7.75
4.11
2.29
17.98
19.02
Operating Margin (%)
7
10
12
13
19
29
63
120
113
120
- -
Depreciation Expense
49
88
71
69
150
133
53
17
-20
253
324
Net Income, GAAP
15.11
14.76
12.57
12.51
14.7
11.91
7.06
- -
- -
12.18
11.25
Effective Tax Rate (%)
19.17
22.12
16.92
16.1
19.31
13.34
5.15
1.65
-1.68
15.06
18.99
Profit Margin (%)
39
60
137
89
838
1,096
547
485
389
567
729
Working Capital
1
1
1
34
- -
575
570
602
555
25
345
LT Debt
155
223
325
378
1,379
1,619
1,541
1,509
1,465
2,186
2,319
Total Equity
- -
45.51
26.26
18.72
16.19
7.13
2.38
- -
- -
10.86
12.31
Return on Invested Capital (%)
- -
46.93
26.01
18.24
15.96
7.22
3.01
- -
- -
11.1
12.41
Return on Capital (%)
- -
46.81
26.08
19.57
17.09
8.86
3.34
1.1
-1.36
13.94
14.85
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
202
202
171
LT Borrowings
140
262
345
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
202
202
202
Market Capitalization
4,809
4,451
4,258

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,499
1,542
1,399
Cash, Cash Equivalents & STI
610
573
477
Accounts Receivable, Net
442
418
421
Inventories
276
285
311
Total Current Liabilities
778
754
670
Payables & Accruals
- -
- -
- -
ST Debt
202
202
171
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
11.36%
49.22%
Free Cash Flow
- -
-16.58%
-193.79%
Net Income, GAAP
- -
-343.23%
-1,356.01%
Sales/Revenue/Turnover
- -
17.66%
40.07%
Total Cash Common Dividend
- -
141.87%
-15.61%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
207
229
356
408
1,200
2025
399
423
- -
422
1,681
2026
458
407
420
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.22
0.03
0.17
-0.12
2025
0.27
0.39
- -
0.32
1.33
2026
0.38
0.64
0.26
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.28
0.02
0.05
0.36
2025
0.02
0.13
- -
0.01
0.26
2026
0.01
0.01
0.51
- -
- -
Business
Hvsen Biotechnology Co., Ltd. (300871.SZ) develops, manufactures, and sells in-vitro diagnostic reagents and instruments primarily focused on clinical chemistry, immunoassay, and molecular diagnostics; its core product portfolio includes chemiluminescence immunoassay analyzers and reagents under the HYBRiD brand, biochemical analyzers, PCR-based nucleic acid extraction systems, and supporting consumables such as test kits for tumor markers, infectious diseases, and cardiac biomarkers. The company serves hospitals, clinics, and diagnostic laboratories in China and select international markets including Southeast Asia and Europe. Founded in 2000 and headquartered in Wuhan, China, Hvsen operates through subsidiaries like Wuhan Huasen Biological Technology Co., Ltd., emphasizing automated diagnostic solutions for high-throughput testing. In the diagnostics industry, Hvsen targets secondary and tertiary hospitals as primary customers, with expanding reach into primary care facilities and export channels. The company recently launched advanced chemiluminescence immunoassay systems in 2024, enhancing throughput and sensitivity for multi-parameter testing, alongside a strategic partnership with a leading Southeast Asian distributor to bolster regional market penetration. No major acquisitions or funding rounds reported in the last two years, though operational expansions include upgraded manufacturing facilities in Wuhan to meet rising domestic demand for COVID-19 and post-pandemic testing solutions.